Shot in the arm for SAMA publishing by Bateman, Chris
The departure of Peter Roberts, head of
our Health and Medical Publishing
Group (HMPG) this December after 20
years of forging it into a highly
successful operation has become the
catalyst for an exciting and creative
realignment.
The core business of the HMPG is to
produce 17 periodic medical
publications in about 100 editions
annually with content generation by a
highly skilled and experienced editorial
team. This team will remain directly
accountable to the South African
Medical Association (SAMA).
However, with some lateral thinking,
a deal has emerged in which the HMPG
business team (production, marketing,
advertising, distribution) will partner
Andrew Fehrsen, founder and MD of
one of the country’s largest business to
business publishing houses, Cape
Media.
Replacing institutional memory and
specialist hands-on ability like that
which Roberts has was never going to
be an easy task, yet the current deal will
open even more doors and optimise the
HMPG operation.
Fehrsen, who has created over 100
jobs in Cape Media over the past 6
years, said at a ceremony to sign the
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might fail to achieve therapeutic levels
while facing a negligible toxicity risk.
Pepper said work on the human
genome would take far longer, ‘because
we don’t yet know enough about the
metabolism of antiretrovirals’.
Meanwhile Roche’s AmpliChip
CYP450 test, which analyses variations
in two genes that play a major role in
the metabolism of almost half of all
drugs currently on the market, received
the CE mark (‘Conformité Européene’),
allowing the test to be used for
diagnostic purposes in the European
Union.
The test detects genetic variations in
the cytochrome P450 2D6 and 2C19
genes and provides the associated
predictive phenotype (poor,
intermediate, extensive, or ultra-rapid
metaboliser). Results can be used by
physicians as an aid for selecting drugs
and individualising treatment doses for
drugs primarily metabolised by the
enzymes these genes encode. 
Roche Diagnostics chief, Heino von
Prondzynski, described the test as the
first representative of an exciting new
technology that held great potential for
diagnostic applications.
The AmpliChip CYP450 test uses two
industry gold standards, Roche
polymerase chain reaction (PCR)
amplification technology and
Affymetrix high-density microarray
technology (glass chips arrayed with
tens of thousands of DNA fragments yet
no bigger than a thumbnail). The
latter’s GeneChip System 3000Dx
instrumentation, on which the
AmpliChip is run, has also been CE
marked.
Enzymes encoded by the CYP2D6
gene metabolise many antidepressants,
antipsychotics, anti-arrhythmics, pain
drugs, antiemetics, and beta-blockers
(beta-adrenergic receptor blocker
drugs). Enzymes encoded by the
CYP2C19 gene metabolise drugs from a
variety of classes, including
anticonvulsants, proton pump
inhibitors, anticoagulants, benzodia-
zepines, and antimalarials.
With AIDS, this new technology may
only be useful for assessing the genetics
of the patient’s ability to metabolise
antiretrovirals and other drugs used in
the treatment of this disease. 
Pepper said one indication of the
‘Machiavellian nature’ of HIV/AIDS,
was that the virus mutated at a rate that
was too quick for AmpliChip
technology to be of use. The Chips were
updated every 2 years, which did not
allow for new mutations to be included
in a timeous manner. He said other
molecular techniques that could be
adapted in a very short space of time to
detect for novel mutations, would have
to be used.
Pepper is a holder of the Walter Johnson
award for post-doctoral research in cell
biology (1974) and the prestigious Denber
Pinard award for his Privat Docent Thesis
(1977).
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SHOT IN THE ARM FOR SAMA PUBLISHING
SAMA Secretary General, Dr Moji Mogare,
signs the new HMPG deal with Cape Media
founder, Andrew Fehrsen.
Cape Media founder and new HMPG partner,
Andrew Fehrsen, with Deputy Editor of the
SAMJ, Professor JP van Niekerk.
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new deal, ‘what makes this such a
pleasure is that the staff have been so
open to change and actually embraced it
after being fully informed’.
Dr Moji Mogare, secretary general of
SAMA, said that even before Roberts
gave notice of his leaving, the SAMA
board had asked him (Mogare) to
oversee the transformation of the HMPG
into an independent business unit.
Mogare, who becomes the executive
director of HMPG, working closely with
Professor Ralph Kirsch and the
Publications Committee, said the deal,
which became effective on 1 January
would ‘unlock value’ in the HMPG staff.
‘This partnership will optimise the
operation here. Andrew is well known
and respected in the publishing industry
and it will open doors for us,’ he said.
The Publications Committee will
constitute the interim board of HMPG
until SAMA’s national council meeting
in July decides on what its new mandate
will be.
Chris Bateman
Peter Roberts, Publisher and Head of the Health and
Medical and Publishing Group (HMPG) takes leave of us at
the end of January 2005 to join his wife who has settled in
the UK. SAMA has been fortunate in having a leader with
his expertise and dedication for 25 years in its publishing
enterprise. 
Peter had 10 years of experience in various publishing
activities before joining the Medical Association as
Advertising Manager in 1979. In this capacity he launched
the CME journal, developed new marketing strategies and
opened a marketing office in Johannesburg, resulting in sales
increases. In 1985 he was appointed Publications Manager
and in 1992 was appointed to his present position.
As Head of the publishing operations Peter has been
responsible for an enterprise that has grown in size and in
stature. There are currently 27 staff members producing 17
successful periodicals published in some 100 editions each
year. Among many achievements Peter initiated,
commissioned and launched the South African Medicines
Formulary, conceptualised and developed South Africa’s
most popular CPD programme, initiated and established the
successful mail-order book sales outlet and considerably
expanded other new business.
Without Peter’s initiative and drive to develop the
business of publishing, the Medical Association would have
found itself in major financial difficulties. For the past 3
years Peter has worked tirelessly towards establishing a
sounder and more viable independent business unit for the
publishing group. This has culminated in the agreements
reported elsewhere in this issue of the SAMJ. His sacrifices in
remaining with the HMPG until succession plans were
properly developed were typical of his loyalty to SAMA.
While these achievements are readily visible, his
contribution to staff development and their satisfaction are
equally important. Publishing entails a delicate balance
between the demands of the market and the editorial
content, which are not always compatible. Peter’s
relationship with the editors has been a winning
combination of mutual respect and cooperation. 
For family reasons, Peter and his wife Cathy are going to
settle in the UK for the foreseeable future, and we wish him
and Cathy all the very best in their new life together.
Dan Ncayiyana, JP van Niekerk     
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FAREWELL TO PETER ROBERTS
Outgoing head of HMPG, Peter Roberts
